ETF Showdown: XBI vs PBE, Which Biotech Fund Wins?
XBI and PBE both bet on biotech, but their structures pull in opposite directions when markets turn volatile. Knowing which one fits your risk appetite could mean the difference between riding a catalyst wave and surviving the next sector wipeout.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
At first glance, SPDR S&P Biotech ETF (NYSEARCA:XBI) and Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) look like two flavors of the same bet on drug discovery. However, the structures diverge sharply. XBI spreads bets almost evenly across more than a hundred biotech names, while PBE runs a concentrated, quant-screened book anchored by large-cap incumbents. That structural gap explains why XBI has ripped 72.6% higher over the past year while PBE returned 34.7%, and why the ranking reverses in tougher markets.
What Each Fund Is Actually Betting On
XBI tracks the S&P Biotechnology Select Industry Index using a modified equal-weight rule. No single name dominates: top holding Apogee Therapeutics weighs in at 1.49%, followed by Twist Bioscience and Moderna, each at 1.41%. The top 10 combined weight is just 13.3%. The implicit bet is biotech beta: small- and mid-cap clinical-stage developers get equal footing with mega-caps, so a hot readout from a $2 billion company moves the fund almost as much as one from a $30 billion one. This amplifies gains during risk-on catalyst cycles and punishes the fund during rate shocks that starve unprofitable biotechs of capital.
PBE takes the opposite approach. Its Dynamic Biotech & Genome Intellidex screens on momentum, earnings, quality, and value, then applies tiered weights to a much shorter list. The 30-position portfolio leans more heavily on profitable incumbents: Vertex Pharmaceuticals at 5.18%, Biogen at 5.08%, and Amgen at 4.9%. PBE is effectively betting that fundamentals and quality factors beat lottery-ticket clinical bets over time.
Where the Difference Shows Up
The 2026 rebound in speculative biotech has been kind to XBI. Year to date, it is up 24.9% against PBE’s 9.1%. Over 10 years, XBI’s equal-weight tilt has produced a 156.7% total return, versus 125.7% for PBE.
Stretch the window differently and PBE’s defensive posture matters. Over the trailing five years, a period that included the brutal 2021-2022 biotech drawdown, returns were essentially the same: 20.1% for PBE versus 20.3% for XBI.
Cash, large-cap names, and a quality screen cushioned the fall while XBI’s small-cap developers were cut in half.
The Practical Comparison
| Metric | XBI | PBE |
|---|---|---|
| Methodology | Modified equal-weight | Quant Intellidex, tiered |
| Holdings | 100+ (top 10 = 13.6%) | ~30 positions (top 10 = 44.5%) |
| Top holding weight | 1.49% (Apogee) | 5.18% (Vertex) |
| Net assets | $10.7 billion | $280.3 million |
| Expense ratio | 0.35% | ~0.58% (historical) |
| YTD return | 24.9% | 9.1% |
| 5-year return | 20.3% | 20.1% |
The Verdict
For a retirement-focused investor who wants biotech exposure without severe drawdowns, PBE tends to offer the smoother structural profile. Its large-cap tilt, quality screen, and standing cash sleeve produce a smoother ride, and the five-year record shows the trade-off works when small-cap biotech breaks down. Investors chasing biotech beta, particularly those who believe the FDA approval cycle and rate-cut backdrop favor clinical-stage names, will find XBI’s equal-weight engine more powerful, and its 0.35% fee is a meaningful advantage.
What would flip the call? A sustained rate-cutting cycle plus another IPO-friendly funding window would tilt the math decisively back to XBI. A credit tightening or a run of high-profile Phase 3 failures pushes it the other direction.
Contact [email protected] for any questions or corrections.
Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.
Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.
Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.
Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.
